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Letter to the Editor
A sound approach: Hydroxychloroquine reduces
mortality in severe COVID-19
To the Editor:
In response:
We thank those submitting letters. It is important to critically
review COVID-19 experience in a peer-reviewed, non-politicized
process, and we fully support appropriately powered double-blind,
randomized trials to address questions on COVID-19 clinical
management. Many letters discussed several similar points, which
we will address jointly. Corticosteroids (MPD) were controlled for
in the multivariate and propensity analyses as were age and
comorbidities, including cardiac disease and severity of illness. Age
was an independent risk factor associated with mortality. We do
feel that steroids have a role in reducing mortality for COVID-19
and were first to publish this (Fadel et al., 2020), however in this
study, HCQ was independently associated with decreased mortali-
ty, a distinct benefit from the steroid effect. We agree with
Wiseman that prospective evaluation of a stage-and-age-nuanced
approach to COVID-19 that exploits the multiple mechanisms of
HCQ and synergy with MPD is needed. In response to Malviya, we
reported 91% of all patients began treatment within two days of
admission. We agree that early therapy is of most benefit; however,
we do not have information on the duration of symptoms prior to
hospitalization. The mSOFA has been validated in other studies (de
Grooth et al., 2017; Grissom et al., 2010); moreover, we also used
hypoxia as an independent marker of disease severity. In response
to Thornton, HCQ was used throughout the study period, limiting
time bias. We used dosages that followed FDA guidelines, with
monitoring for cardiac arrhythmias. All centers used the same
treatment guideline minimizing treatment bias. The protocol we
used was previously published (Fadel et al., 2020). In response to
Atkinson, patients assigned to the HCQ group had a moderate and
severe illness at presentation, which would favor worse outcomes
with HCQ. The exclusion of patients with premorbid risk for cardiac
toxicity is similar to clinical trials of many other drugs such as
remdesivir, where individuals with severe liver or kidney disease
were excluded (Clinical Trial, 2020).
Importantly, in response to Rosenberg, our study differed from
other studies, including randomized controlled trials (RCTs), in a
variety of ways, including the number of patients, comorbidities,
the severity of illness and dosage and timing of administration of
HCQ (WHO, 2020; New Indian Express, 2020; Mikami et al., 2020).
Prior studies have major limitations with timing, dosing, cardiac AE
monitoring, and therapeutic windows. To date, there has been no
properly designed and powered RCT that evaluates HCQ treatment
for COVID-19. Concerning our comments about the Rosenberg
paper, a variety of serious limitations in that paper should be
corrected on the record. The critical limitation, among many
others, is that patients receiving HCQ with or without azithromy-
cin (AZM) were overall sicker on presentation and had multiple
other risk factors; Black or Hispanic patients were likely to receive
HCQ or AZM (mortality is significantly higher in these groups).
Patients receiving HCQ were more likely to be obese, diabetic, have
chronic lung disease, and cardiovascular conditions, yet these
sicker patients had approximately the same mortality rates
compared to patients with a milder course of the disease and
fewer risk factors. However, the authors incorrectly conclude that
“there are no significant benefits.” It is noteworthy that HCQ was
associated with a significant survival benefit in a larger cohort of
patients from New York City, as reported by Mikami et al. (2020).
In these unprecedented times, the role, cost-benefit, and
availability of repurposed agents such as HCQ and newer drugs
such as remdesivir should be urgently evaluated in an impartial
manner. Remdesivir is a novel drug with a novel approach and has
a place in the COVID-19 treatment formulary; however, it is
expensive, and there is limited availability outside of the United
States (Forbes, 2020; Finley, 2020).
Our paper's overarching theme is that a safe dosage and early
utilization of hydroxychloroquine reduced mortality in hospital-
ized patients. Similar published large cohort studies support our
findings from New York City and France (Mikami et al., 2020; Lagier
et al., 2020) As stated in our paper, further prospective studies are
needed.
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